Evaluating SARS-CoV-2 bivalent booster vaccine against severe COVID-19 outcomes medrxivpreprint THLorg SARSCoV2 COVID19 BivalentBoosterVaccine
By Bhavana KunkalikarMar 9 2023Reviewed by Aimee Molineux *Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
In prior research, bivalent vaccinations have been shown to boost protection against severe disease outcomes. The duration of this protection, however, is still unknown. Hence, research predicting the long-term efficacy of bivalent immunizations is required as policymakers consider recommending a second bivalent booster.
Furthermore, almost one-third of the bivalent-vaccinated persons received Comirnaty BA.1, and the remaining two-thirds were vaccinated with Comirnaty BA.4-5. Bivalent Spikevax vaccinations were utilized in minute dosages. In examining negative control outcomes, the team identified 9447 visits to the emergency room owing to injury among elderly persons and 2173 visits among the chronically ill. There was no difference in injury risk between individuals who were and were not vaccinated with a bivalent vaccine. Nonetheless, chronically unwell individuals appeared to have a modestly greater risk of harm.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The effect of variation of individual infectiousness on SARS-CoV-2 transmission in householdsHousehold transmission modeling qualified variation of individual infectiousness among infected persons, which could be caused by both biological factors and host behaviors.
Read more »
Long-term gastrointestinal outcomes of COVID-19 - Nature CommunicationsSARS-CoV-2 infection can lead to varied post-acute symptoms in the lungs and other organs, including the gastrointestinal system. Here the authors estimate the risks and 1-year burdens of a set of pre-specified incident gastrointestinal outcomes following SARS-CoV-2 infection in an electronic health care record-based cohort study.
Read more »
Self-directed autoantibodies against certain chemokines may protect against long-COVIDA recent study published in the journal Nature Immunology discovered autoantibodies against chemokines following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Read more »
Early outpatient treatment of COVID-19 with metformin could reduce the risk of developing long COVIDIn a recent study posted to Preprints with The Lancet*, a team of researchers from the United States investigated whether early outpatient treatment of coronavirus disease 2019 (COVID-19) patients with fluvoxamine, ivermectin, or metformin could prevent long coronavirus disease (long COVID).
Read more »
Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chipsAbstract. SARS-CoV-2 induces severe organ damage not only in the lung but also in the liver, heart, kidney, and intestine. It is known that COVID-19 severity co
Read more »